|
[1] D'SOUZA AA,DEVARAJAN PV. Asialoglycoprotein receptor mediated hepatocyte targeting-strategies and applications[J]. J Control Release,2015,203:126-139.
|
|
[2] HUBER M,KEPPLER D. Eicosanoids and the liver[J]. Prog Liver Dis,1990,9:117-141.
|
|
[3] ABECASSIS M,FALK JA,MAKOWKA L,et al. 16,16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection[J]. J Clin Invest,1987,80(3):881-889.
|
|
[4] MOHAMED YS,ABDELSALAM RM,ATTIA AS,et al. Regulation of liver regeneration by prostaglandin E2 and thromboxane A2 following partial hepatectomy in rats[J]. Naunyn Schmiedebergs Arch Pharmacol,2020,393(8):1437-1446.
|
|
[5] SHIMADA H,HASHIMOTO R,AOKI A,et al. The regulatory mechanism involved in the prostaglandin E2 disposition in carbon tetrachloride-induced liver injury[J]. Prostaglandins Leukot Essent Fatty Acids,2020,155:102081.
|
|
[6] NAKANISHI M,ROSENBERG DW. Multifaceted roles of PGE2in inflammation and cancer[J]. Semin Immunopathol,2013,35(2):123-137.
|
|
[7] RICCIOTTI E,FITZGERALD GA. Prostaglandins and inflammation[J]. Arterioscler Thromb Vasc Biol,2011,31(5):986-1000.
|
|
[8] CAO Y,NISHIHARA R,WU K,et al. Population-wide impact of long-term use of aspirin and the risk for cancer[J]. JAMA Oncol,2016,2(6):762-769.
|
|
[9] ZHAO X,XU Z,LI H. NSAIDs use and reduced metastasis in cancer patients:Results from a meta-analysis[J]. Sci Rep,2017,7(1):1875.
|
|
[10] Coxib and traditional NSAID Trialists'(CNT)Col aboration,BHALA N,EMBERSON J,et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs:Meta-analyses of individual participant data from randomised trials[J]. Lancet,2013,382(9894):769-779.
|
|
[11] PARK JY,PILLINGER MH,ABRAMSON SB. Prostaglandin E2synthesis and secretion:The role of PGE2 synthases[J]. Clin Immunol,2006,119(3):229-240.
|
|
[12] MURAKAMI M,KUDO I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway[J]. Prog Lipid Res,2004,43(1):3-35.
|
|
[13] HARA S,KAMEI D,SASAKI Y,et al. Prostaglandin E synthases:Understanding their pathophysiological roles through mouse genetic models[J]. Biochimie,2010,92(6):651-659.
|
|
[14] SELZNER N,RUDIGER H,GRAF R,et al. Protective strategies against ischemic injury of the liver[J]. Gastroenterology,2003,125(3):917-936.
|
|
[15] HUCKLE WR,HEPLER JR,RHEE SG,et al. Protein kinase C inhibits epidermal growth factor-dependent tyrosine phosphorylation of phospholipase C gamma and activation of phosphoinositide hydrolysis[J]. Endocrinology,1990,127(4):1697-1705.
|
|
[16] YAMADA T,TAKUSAGAWA F. PGH2 degradation pathway catalyzed by GSH-heme complex bound microsomal prostaglandin E2 synthase type 2:The first example of a dual-function enzyme[J]. Biochemistry,2007,46(28):8414-8424.
|
|
[17] NAKATANI Y,HOKONOHARA Y,TAJIMA Y,et al. Involvement of the constitutive prostaglandin E synthase cPGES/p23in expression of an initial prostaglandin E2 inactivating enzyme,15-PGDH[J]. Prostaglandins Other Lipid Mediat,2011,94(3-4):112-117.
|
|
[18] NISHIZAWA N,ITO Y,ESHIMA K,et al. Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice[J]. J Hepatol,2018,69(1):110-120.
|
|
[19] YAO L,CHEN W,HAN C,et al. Microsomal prostaglandin E synthase-1 protects against Fas-induced liver injury[J].Am J Physiol Gastrointest Liver Physiol,2016,310(11):G1071-1080.
|
|
[20] PIANKO S,PATELLA S,OSTAPOWICZ G,et al. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption,and may be associated with hepatic fibrosis:Mechanisms of liver cell injury in chronic hepatitis C virus infection[J]. J Viral Hepat,2001,8(6):406-413.
|
|
[21] SHARMA AD,NARAIN N,HNDEL EM,et al. MicroRNA-221 regulates FAS-induced fulminant liver failure[J]. Hepatology,2011,53(5):1651-1661.
|
|
[22] IBRAHIM SH,HIRSOVA P,GORES GJ. Non-alcoholic steatohepatitis pathogenesis:Sublethal hepatocyte injury as a driver of liver inflammation[J]. Gut,2018,67(5):963-972.
|
|
[23] SAYINER M,KOENIG A,HENRY L,et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the united states and the rest of the world[J]. Clin Liver Dis,2016,20(2):205-214.
|
|
[24] HENKEL J,FREDE K,SCHANZE N,et al. Stimulation of fat accumulation in hepatocytes by PGE-dependent repression of hepatic lipolysis，β-oxidation and VLDL-synthesis[J].Lab Invest,2012,92(11):1597-1606.
|
|
[25] TIAN Z,CHEN Y,GAO B. Natural killer cells in liver disease[J]. Hepatology,2013,57(4):1654-1662.
|
|
[26] HENKEL J,COLEMAN CD,SCHRAPLAU A,et al. Augmented liver inflammation in a microsomal prostaglandin E synthase 1(m PGES-1)-deficient diet-induced mouse NASH model[J]. Sci Rep,2018,8(1):16127.
|
|
[27] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
|
[28] LU D,HAN C,WU T. Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis[J]. Oncogene,2012,31(7):842-857.
|
|
[29] BLBL B,KKGZEL I·．Microsomal prostaglandin E2synthase-1 as a new macromolecular drug target in the prevention of inflammation and cancer[J]. Anticancer Agents Med Chem,2019,19(10):1205-1222.
|
|
[30] LIU C,CHEN S,WANG X,et al. 15d-PGJ2decreases PGE2synthesis in HBx-positive liver cells by interfering EGR1 binding to m PGES-1 promoter[J]. Biochem Pharmacol,2014,91(3):337-347.
|
|
[31] RUAN D,SO SP. Prostaglandin E2 produced by inducible COX-2 and m PGES-1 promoting cancer cell proliferation in vitro and in vivo[J]. Life Sci,2014,116(1):43-50.
|
|
[32] MA Y,WANG X,TANG N. Downregulation of m PGES-1 expression via EGR1 plays an important role in inhibition of caffeine on PGE2 synthesis of HBx(+)hepatocytes[J]. Mediators Inflamm,2015,2015:372750.
|
|
[33] CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al. ACG Clinical Guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol,2014,109(7):950-966; quiz 967.
|
|
[34] REUBEN A,KOCH DG,LEE WM. Drug-induced acute liver failure:Results of a U. S. multicenter,prospective study[J].Hepatology,2010,52(6):2065-2076.
|
|
[35] ELSNER M,GULDBAKKE B,TIEDGE M,et al. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin[J]. Diabetologia,2000,43(12):1528-1533.
|
|
[36] DUFRANE D,van STEENBERGHE M,GUIOT Y,et al. Streptozotocin-induced diabetes in large animals(pigs/primates):Role of GLUT2 transporter and beta-cell plasticity[J].Transplantation,2006,81(1):36-45.
|
|
[37] SUN Y,JIA Z,YANG G,et al. m PGES-2 deletion remarkably enhances liver injury in streptozotocin-treated mice via induction of GLUT2[J]. J Hepatol,2014,61(6):1328-1336.
|
|
[38] WANG H,ZHANG R,ZHU Y,et al. Microsomal prostaglandin E synthase 2 deficiency is resistant to acetaminophen-induced liver injury[J]. Arch Toxicol,2019,93(10):2863-2878.
|
|
[39] NAKATANI Y,HOKONOHARA Y,KAKUTA S,et al. Knockout mice lacking cPGES/p23,a constitutively expressed PGE2synthetic enzyme,are peri-natally lethal[J]. Biochem Biophys Res Commun,2007,362(2):387-392.
|
|
[40] LOVGREN AK,KOVAROVA M,KOLLER BH. cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis[J]. Mol Cell Biol,2007,27(12):4416-4430.
|
DownLoad: